Danny Liu

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CART) therapy

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement Read More »

Guidance to the Implementation and operational management of marketed CAR T-cell therapy – by the GoCART Coalition Pharmacist Working Group

The GoCART Coalition is delighted to announce that its Pharmacist Working Group has published a guidance document on the Implementation and operational management of marketed CAR T-cell therapy. You can find

Guidance to the Implementation and operational management of marketed CAR T-cell therapy – by the GoCART Coalition Pharmacist Working Group Read More »